Silencing of CtBP1 suppresses the migration in human glioma cells

Chengjin Zhao,Yifen Shen,Xuelei Tao,Jian Xu,Junjie Lu,Chao Liu,Zhiwei Xu,Qing Tang,Tao Tao,Xiubing Zhang
DOI: https://doi.org/10.1007/s10735-016-9678-z
2016-01-01
Journal of Molecular Histology
Abstract:Carboxyl-terminal binding protein 1 (CtBP1), up-regulated in various types of human cancers, has been functionally associated with proliferation, anti-apoptosis, and EMT in vitro studies. However, the functional significance of CtBP1 in the pathophysiology of glioma remains unknown. In the present study, we showed the expression of CtBP1 was markedly higher in glioma tissues compared with normal brain tissues by Western blot analysis. Immunohistochemical analysis revealed that CtBP1 mainly localized in the nucleus of glioma cells. Statistical analysis suggested the upregulation of CtBP1 was considerably correlated with the WHO grade ( P < 0.05) and those patients with high CtBP1 levels exhibited shorter survival time ( P < 0.01). Silencing CtBP1 by short hairpin RNAi caused an inhibition of cell migration. Moreover, knockdown of CtBP1 increases E-cadherin expression and decreases vimentin expression. These data uncovered that CtBP1 protein is a valuable marker of glioma pathogenic process and that CtBP1 can serve as a novel prognostic marker for glioma therapy.
What problem does this paper attempt to address?